Trial | NCT00406094  Report issue

Title

Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)
The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    montelukast ...

  • Study Participants

    6
The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.
Patients will receive either montelukast or placebo in the treatment of NARES. 4 visits will be conducted over 12 weeks. A history and physical will be performed at the beginning of the trial and at the end. Skin testing will be done at Visit 1. Nasal smears and lavages will be performed at every visit. Patients will be compensated for time and travel.
Study Started
Nov 30
2006
Primary Completion
Dec 31
2009
Anticipated
Study Completion
Dec 31
2009
Anticipated
Last Update
Jan 16
2009
Estimate

Drug montelukast

10mg

  • Other names: Singulair

Drug placebo

placebo

1 Experimental

montelukast

2 Placebo Comparator

placebo

Criteria 

Inclusion Criteria:

Aged 18 - 65 years
Diagnosed with NARES

Exclusion Criteria:

Smokers, exposed to passive smoke
Diagnosis of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), or vasomotor rhinitis (VMR)
No Results Posted